Piper Sandler raised the firm’s price target on Teva (TEVA) to $42 from $41 and keeps an Overweight rating on the shares following quarterly results. The firm notes Teva continues to guide to 2026 total revenue of $16.4B-$16.8B, a decline of about 4% versus 2025 at the midpoint. With high visibility into significant expansion of the neuroscience segment, along with continued advancement of the immunology-focused pipeline, further multiple expansion from a current EV/2027 EBITDA of about nine times is in order, adds Piper.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva price target raised to $42 from $36 at UBS
- Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
- Teva price target raised to $45 from $42 at Truist
- Unusually active option classes on open April 29th
- Teva says making ‘great progress’ on Pivot to Growth strategy